---
title: "Glycomimetics | 10-Q: FY2025 Q1 EPS Beats Estimate at USD -0.04"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240237425.md"
datetime: "2025-05-14T21:08:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240237425.md)
  - [en](https://longbridge.com/en/news/240237425.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240237425.md)
generator: "portal-rs"
---

# Glycomimetics | 10-Q: FY2025 Q1 EPS Beats Estimate at USD -0.04

EPS: As of FY2025 Q1, the actual value is USD -0.04, beating the estimate of USD -0.05.

### Operational Metrics

-   **Net Loss**: GlycoMimetics, Inc. reported a net loss of $2.3 million for the three months ended March 31, 2025, compared to a net loss of $10.7 million for the same period in 2024, representing a decrease of 78%.
-   **Research and Development Expense**: The company reported a significant decrease in research and development expenses to $15,000 for the three months ended March 31, 2025, from $6.0 million in the same period in 2024, a 100% decrease.
-   **General and Administrative Expense**: These expenses decreased to $2.4 million for the three months ended March 31, 2025, from $5.1 million in the same period in 2024, a 53% decrease.

### Cash Flow

-   **Net Cash Used in Operating Activities**: The company used $5.1 million in operating activities for the three months ended March 31, 2025, compared to $10.5 million in the same period in 2024.

### Future Outlook and Strategy

-   **Merger and Strategic Alternatives**: GlycoMimetics, Inc. has entered into a Merger Agreement with Crescent Biopharma, Inc., expected to close in the second quarter of 2025. The merger will result in Crescent becoming a wholly owned subsidiary, and the combined entity will operate under the name Crescent Biopharma, Inc. The merger is contingent upon stockholder approval and other customary closing conditions.
-   **Private Placement**: Concurrently with the merger, a private placement is expected to raise approximately $200.0 million, contingent on the merger’s completion.
-   **Going Concern**: The company has expressed substantial doubt about its ability to continue as a going concern beyond one year from the issuance of the financial statements without the completion of the merger and private placement. If these do not occur by the third quarter of 2025, the company may seek other strategic alternatives or liquidate.

### Related Stocks

- [GLYC.US](https://longbridge.com/en/quote/GLYC.US.md)
- [CBIO.US](https://longbridge.com/en/quote/CBIO.US.md)

## Related News & Research

- [Kaiser Aluminum (KALU) Stock Dropped, So What Is Driving Attention Now?](https://longbridge.com/en/news/296564710.md)
- [Insider Unloading: Michael Saks Sells $410K Worth Of RCM Technologies Shares](https://longbridge.com/en/news/296633661.md)
- [Everett Harris & Co. CA Makes New Investment in Procter & Gamble Company (The) $PG](https://longbridge.com/en/news/296451542.md)
- [MDU Resources Group (MDU) Has Investors Looking Closer After Its Latest Update](https://longbridge.com/en/news/296100341.md)
- [Stevanato Group (STVN) Updated Guidance, Is It Still Below Fair Value?](https://longbridge.com/en/news/296070806.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**